Cargando…
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications
The abnormal BCR-ABL oncoprotein is a constitutively active tyrosine kinase driving aberrant proliferation of transformed hematopoietic cells. BCR-ABL regulates activation of many mitogenic and pro-survival pathways, including the PI 3'K/AKT/mTOR pathway that controls various effectors and regu...
Autores principales: | Vakana, Eliza, Platanias, Leonidas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282089/ https://www.ncbi.nlm.nih.gov/pubmed/22249159 |
Ejemplares similares
-
Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells
por: Vakana, Eliza, et al.
Publicado: (2013) -
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
por: Cario, Gunnar, et al.
Publicado: (2020) -
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
por: Carofiglio, Francesca, et al.
Publicado: (2020) -
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias
por: Curi, Dany A., et al.
Publicado: (2015) -
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)